Chemoradiotherapy for Extrahepatic Bile Duct Cancer with Gross Residual Disease after Surgery

摘要: BACKGROUND The purpose of the present study was to analyze outcome chemoradiotherapy for extrahepatic bile duct (EHBD) cancer patients with gross residual disease after surgical resection. PATIENTS AND METHODS We retrospectively analyzed 30 EHBD adenocarcinoma who underwent palliative resection (R2 resection). Postoperative radiotherapy delivered tumor bed including and regional lymph nodes (range=40-55.8 Gy). Most concurrently 5-fluorouracil (5-FU) or gemcitabine. RESULTS 2-year locoregional progression-free, distant metastasis-free overall survival rates were 33.3%, 42.4% 44.5%, respectively. High radiation dose≥50 Gy had a marginally significant impact on superior progression-free compared 40 (p=0.081). One patient developed grade 3 late gastrointestinal toxicity. CONCLUSION Adjuvant surgery well-tolerated. There could be chance durable control even long-term in selected patients.